Intest Res.  2018 Apr;16(2):168-177. 10.5217/ir.2018.16.2.168.

Predicting outcomes to optimize disease management in inflammatory bowel disease in Japan: their differences and similarities to Western countries

Affiliations
  • 1Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan.
  • 2The Third Department of Internal Medicine, Kyorin University School of Medicine, Mitaka, Japan. thisamatsu@ks.kyorin-u.ac.jp
  • 3Department of Internal Medicine, Toho University Sakura Medical Center, Sakura, Japan.
  • 4Center for Diagnostic and Therapeutic Endoscopy, Keio University School of Medicine, Tokyo, Japan.
  • 5Department of Gastroenterology, Shiga University of Medical Science, Otsu, Japan.
  • 6Department of Gastrointestinal and Pediatric Surgery, Mie University Graduate School of Medicine, Tsu, Japan.
  • 7Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan.
  • 8Department of Gastroenterology and Hepatology, Graduate School of Medicine, Osaka University, Suita, Japan.
  • 9Department of Inflammatory Bowel Disease, Division of Surgery, Hyogo College of Medicine, Nishinomiya, Japan.
  • 10Department of Gastroenterology and Hematology, Hirosaki National Hospital, Hirosaki, Japan.
  • 11Department of Gastroenterology and Hepatology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan.
  • 12Inflammatory Bowel Disease Center, Yokohama City University Medical Center, Yokohama, Japan.
  • 13Division of Gastroenterology, Department of Internal Medicine, School of Medicine, Iwate Medical University, Morioka, Japan.
  • 14IBD Center, Sapporo-Kosei General Hospital, Sapporo, Japan.
  • 15Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan.
  • 16Department of Inflammatory Bowel Disease, Hyogo College of Medicine, Nishinomiya, Japan.
  • 17Department of Gastroenterology and Hepatology, Sapporo Medical University School of Medicine, Sapporo, Japan.
  • 18Department of Gastroenterology and Hepatology, Higashi-Ohmi General Medical Center, Higashiomi, Japan.
  • 19Division of Gastroenterology, Department of Internal Medicine, Aichi Medical University School of Medicine, Nagakute, Japan.
  • 20Department of Gastroenterology, Kitasato University School of Medicine, Sagamihara, Japan.
  • 21Division of Gastroenterology, Department of Medicine, Tokyo Yamate Medical Center, Tokyo, Japan.
  • 22Department of Intestinal Inflammation Research, Hyogo College of Medicine, Nishinomiya, Japan.
  • 23Medical Affairs, Medical, AbbVie GK, Tokyo, Japan.

Abstract

Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is a chronic inflammatory disease of the gastrointestinal tract, with increasing prevalence worldwide. IBD Ahead is an international educational program that aims to explore questions commonly raised by clinicians about various areas of IBD care and to consolidate available published evidence and expert opinion into a consensus for the optimization of IBD management. Given differences in the epidemiology, clinical and genetic characteristics, management, and prognosis of IBD between patients in Japan and the rest of the world, this statement was formulated as the result of literature reviews and discussions among Japanese experts as part of the IBD Ahead program to consolidate statements of factors for disease prognosis in IBD. Evidence levels were assigned to summary statements in the following categories: disease progression in CD and UC; surgery, hospitalization, intestinal failure, and permanent stoma in CD; acute severe UC; colectomy in UC; and colorectal carcinoma and dysplasia in IBD. The goal is that this statement can aid in the optimization of the treatment strategy for Japanese patients with IBD and help identify high-risk patients that require early intervention, to provide a better long-term prognosis in these patients.

Keyword

Crohn disease; Colitis, ulcerative; Prognosis; Colorectal neoplasms; Consensus

MeSH Terms

Asian Continental Ancestry Group
Colectomy
Colitis, Ulcerative
Colorectal Neoplasms
Consensus
Crohn Disease
Disease Management*
Disease Progression
Early Intervention (Education)
Epidemiology
Expert Testimony
Gastrointestinal Tract
Hospitalization
Humans
Inflammatory Bowel Diseases*
Japan*
Prevalence
Prognosis

Cited by  2 articles

Efficacy and safety of abrilumab, an α4β7 integrin inhibitor, in Japanese patients with moderate-to-severe ulcerative colitis: a phase II study
Toshifumi Hibi, Satoshi Motoya, Toshifumi Ashida, Souken Sai, Yukinori Sameshima, Shiro Nakamura, Atsuo Maemoto, Masahiro Nii, Barbara A Sullivan, Robert A. Gasser Jr, Yasuo Suzuki
Intest Res. 2019;17(3):375-386.    doi: 10.5217/ir.2018.00141.

Precision medicine in inflammatory bowel diseases
Ashwin N. Ananthakrishnan
Intest Res. 2024;22(1):8-14.    doi: 10.5217/ir.2023.00087.


Reference

1. Torres J, Caprioli F, Katsanos KH, et al. Predicting outcomes to optimize disease management in inflammatory bowel diseases. J Crohns Colitis. 2016; 10:1385–1394. PMID: 27282402.
Article
2. Hida N, Nakamura S, Hahm KB, et al. A questionnaire-based survey on the diagnosis and management of inflammatory bowel disease in East Asian countries in 2012. Digestion. 2014; 89:88–103. PMID: 24458117.
Article
3. Park SJ, Kim WH, Cheon JH. Clinical characteristics and treatment of inflammatory bowel disease: a comparison of Eastern and Western perspectives. World J Gastroenterol. 2014; 20:11525–11537. PMID: 25206259.
Article
4. Prideaux L, Kamm MA, De Cruz PP, Chan FK, Ng SC. Inflammatory bowel disease in Asia: a systematic review. J Gastroenterol Hepatol. 2012; 27:1266–1280. PMID: 22497584.
Article
5. Fuyuno Y, Yamazaki K, Takahashi A, et al. Genetic characteristics of inflammatory bowel disease in a Japanese population. J Gastroenterol. 2016; 51:672–681. PMID: 26511940.
Article
6. Hirano A, Yamazaki K, Umeno J, et al. Association study of 71 European Crohn’s disease susceptibility loci in a Japanese population. Inflamm Bowel Dis. 2013; 19:526–533. PMID: 23388546.
Article
7. Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn’s disease. Gastroenterology. 2006; 130:650–656. PMID: 16530505.
Article
8. Leong RW, Lau JY, Sung JJ. The epidemiology and phenotype of Crohn’s disease in the Chinese population. Inflamm Bowel Dis. 2004; 10:646–651. PMID: 15472528.
Article
9. Ng SC, Tang W, Leong RW, et al. Environmental risk factors in inflammatory bowel disease: a population-based case-control study in Asia-Pacific. Gut. 2015; 64:1063–1071. PMID: 25217388.
Article
10. Sato Y, Matsui T, Yano Y, et al. Long-term course of Crohn’s disease in Japan: incidence of complications, cumulative rate of initial surgery, and risk factors at diagnosis for initial surgery. J Gastroenterol Hepatol. 2015; 30:1713–1719. PMID: 26094852.
Article
11. Arora U, Ananthakrishnan AN, Kedia S, et al. Effect of oral tobacco use and smoking on outcomes of Crohn’s disease in India. J Gastroenterol Hepatol. 2018; 33:134–140. PMID: 28475826.
Article
12. Gearry RB. IBD and environment: are there differences between East and West. Dig Dis. 2016; 34:84–89. PMID: 26982053.
Article
13. Biroulet LP, Loftus EV, Harmsen WS, Zinsmeister AR, Sandborn WJ. T1299 Emergency room visits and hospitalizations for Crohn’s disease in a population-based cohort. Gastroenterol. 2010; 138:S532.
Article
14. Etchevers MJ, Aceituno M, García-Bosch O, et al. Risk factors and characteristics of extent progression in ulcerative colitis. Inflamm Bowel Dis. 2009; 15:1320–1325. PMID: 19235909.
Article
15. Gower-Rousseau C, Dauchet L, Vernier-Massouille G, et al. The natural history of pediatric ulcerative colitis: a populationbased cohort study. Am J Gastroenterol. 2009; 104:2080–2088. PMID: 19436273.
Article
16. Kim B, Park SJ, Hong SP, Kim TI, Kim WH, Cheon JH. Proximal disease extension and related predicting factors in ulcerative proctitis. Scand J Gastroenterol. 2014; 49:177–183. PMID: 24325564.
Article
17. Meucci G, Vecchi M, Astegiano M, et al. The natural history of ulcerative proctitis: a multicenter, retrospective study. Gruppo di Studio per le Malattie Infiammatorie Intestinali (GSMII). Am J Gastroenterol. 2000; 95:469–473. PMID: 10685752.
Article
18. Kuwahara E, Asakura K, Nishiwaki Y, et al. Effects of family history on inflammatory bowel disease characteristics in Japanese patients. J Gastroenterol. 2012; 47:961–968. PMID: 22382632.
Article
19. Fujii T, Sato M, Hosoi K, et al. Assessment of the family history of patients with ulcerative colitis at a single center in Japan. J Pediatr Gastroenterol Nutr. 2016; 63:512–515. PMID: 27352080.
Article
20. Kuwahara E, Murakami Y, Nakamura T, et al. Factors associated with exacerbation of newly diagnosed mild ulcerative colitis based on a nationwide registry in Japan. J Gastroenterol. 2017; 52:185–193. PMID: 27075755.
Article
21. Lee JH, Cheon JH, Moon CM, et al. Do patients with ulcerative colitis diagnosed at a young age have more severe disease activity than patients diagnosed when older. Digestion. 2010; 81:237–243. PMID: 20110709.
Article
22. Anzai H, Hata K, Kishikawa J, et al. Clinical pattern and progression of ulcerative proctitis in the Japanese population: a retrospective study of incidence and risk factors influencing progression. Colorectal Dis. 2016; 18:O97–O102. PMID: 26663677.
Article
23. Chen JH, Andrews JM, Kariyawasam V, et al. Review article: acute severe ulcerative colitis - evidence-based consensus statements. Aliment Pharmacol Ther. 2016; 44:127–144. PMID: 27226344.
Article
24. Dinesen LC, Walsh AJ, Protic MN, et al. The pattern and outcome of acute severe colitis. J Crohns Colitis. 2010; 4:431–437. PMID: 21122540.
Article
25. Kuno T, Kojima Y, Mochizuki H, et al. Factors predicting subsequent hospitalization in patients with ulcerative colitis: total colonoscopic findings are the strongest predictor. Hepatogastroenterology. 2015; 62:821–824. PMID: 26902009.
26. Moayyeri A, Daryani NE, Bahrami H, Haghpanah B, Nayyer-Habibi A, Sadatsafavi M. Clinical course of ulcerative colitis in patients with and without primary sclerosing cholangitis. J Gastroenterol Hepatol. 2005; 20:366–370. PMID: 15740478.
Article
27. Odes HS, Fich A, Reif S, et al. Effects of current cigarette smoking on clinical course of Crohn's disease and ulcerative colitis. Dig Dis Sci. 2001; 46:1717–1721. PMID: 11508673.
28. Nakase H, Keum B, Ye BD, Park SJ, Koo HS, Eun CS. Treatment of inflammatory bowel disease in Asia: the results of a multinational web-based survey in the 2(nd) Asian Organization of Crohn's and Colitis (AOCC) meeting in Seoul. Intest Res. 2016; 14:231–239. PMID: 27433145.
Article
29. Matsumoto S, Yoshida Y. What are the factors that affect hospitalization and surgery for aggravation of ulcerative colitis. Eur J Gastroenterol Hepatol. 2014; 26:282–287. PMID: 24374839.
Article
30. Monstad I, Hovde O, Solberg IC, Moum BA. Clinical course and prognosis in ulcerative colitis: results from population-based and observational studies. Ann Gastroenterol. 2014; 27:95–104. PMID: 24733679.
31. Hoie O, Wolters FL, Riis L, et al. Low colectomy rates in ulcerative colitis in an unselected European cohort followed for 10 years. Gastroenterology. 2007; 132:507–515. PMID: 17258717.
Article
32. Kaplan GG, Seow CH, Ghosh S, et al. Decreasing colectomy rates for ulcerative colitis: a population-based time trend study. Am J Gastroenterol. 2012; 107:1879–1887. PMID: 23165448.
Article
33. Langholz E, Munkholm P, Davidsen M, Binder V. Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology. 1994; 107:3–11. PMID: 8020674.
Article
34. Targownik LE, Singh H, Nugent Z, Bernstein CN. The epidemiology of colectomy in ulcerative colitis: results from a population-based cohort. Am J Gastroenterol. 2012; 107:1228–1235. PMID: 22613902.
Article
35. Falcone RA Jr, Lewis LG, Warner BW. Predicting the need for colectomy in pediatric patients with ulcerative colitis. J Gastrointest Surg. 2000; 4:201–206. PMID: 10675244.
Article
36. Romberg-Camps MJ, Dagnelie PC, Kester AD, et al. Influence of phenotype at diagnosis and of other potential prognostic factors on the course of inflammatory bowel disease. Am J Gastroenterol. 2009; 104:371–383. PMID: 19174787.
Article
37. Solberg IC, Lygren I, Jahnsen J, et al. Clinical course during the first 10 years of ulcerative colitis: results from a population-based inception cohort (IBSEN Study). Scand J Gastroenterol. 2009; 44:431–440. PMID: 19101844.
Article
38. Shah SC, Colombel JF, Sands BE, Narula N. Mucosal healing is associated with improved long-term outcomes of patients with ulcerative colitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2016; 14:1245–1255. PMID: 26829025.
Article
39. Ueno F, Matsui T, Matsumoto T, et al. Evidence-based clinical practice guidelines for Crohn’s disease, integrated with formal consensus of experts in Japan. J Gastroenterol. 2013; 48:31–72. PMID: 23090001.
Article
40. Hata K, Kishikawa J, Anzai H, et al. Surveillance colonoscopy for colitis-associated dysplasia and cancer in ulcerative colitis patients. Dig Endosc. 2016; 28:260–265. PMID: 26096182.
Article
41. Matsuoka H, Ikeuchi H, Uchino M, et al. Clinicopathological features of ulcerative colitis-associated colorectal cancer pointing to efficiency of surveillance colonoscopy in a large retrospective Japanese cohort. Int J Colorectal Dis. 2013; 28:829–834. PMID: 23080343.
Article
42. Mizushima T, Ohno Y, Nakajima K, et al. Malignancy in Crohn’s disease: incidence and clinical characteristics in Japan. Digestion. 2010; 81:265–270. PMID: 20134166.
Article
43. Yano Y, Matsui T, Uno H, Hirai F, Futami K, Iwashita A. Risks and clinical features of colorectal cancer complicating Crohn's disease in Japanese patients. J Gastroenterol Hepatol. 2008; 23:1683–1688. PMID: 18752557.
Article
44. Fujita T, Ando T, Watanabe O, et al. Clinicopathological study of colorectal cancer occurring in patients with ulcerative colitis: results from a single hospital in Japan. Hepatogastroenterology. 2010; 57:487–492. PMID: 20698214.
45. Tanaka A, Takikawa H. Geoepidemiology of primary sclerosing cholangitis: a critical review. J Autoimmun. 2013; 46:35–40. PMID: 23932346.
Article
46. Gupta RB, Harpaz N, Itzkowitz S, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology. 2007; 133:1099–1105. PMID: 17919486.
47. Rubin DT, Huo D, Kinnucan JA, et al. Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case-control study. Clin Gastroenterol Hepatol. 2013; 11:1601–1608. PMID: 23872237.
Article
48. Bopanna S, Ananthakrishnan AN, Kedia S, Yajnik V, Ahuja V. Risk of colorectal cancer in Asian patients with ulcerative colitis: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2017; 2:269–276. PMID: 28404156.
Article
49. Watanabe T, Ajioka Y, Mitsuyama K, et al. Comparison of targeted vs random biopsies for surveillance of ulcerative colitis-associated colorectal cancer. Gastroenterology. 2016; 151:1122–1130. PMID: 27523980.
Article
50. Oriuchi T, Hiwatashi N, Kinouchi Y, et al. Clinical course and longterm prognosis of Japanese patients with Crohn's disease: predictive factors, rates of operation, and mortality. J Gastroenterol. 2003; 38:942–953. PMID: 14614601.
Article
51. Shinozaki M. Crohn's disease and intestinal cancer in Japan. Nippon Daicho Komonbyo Gakkai Zasshi. 2008; 61:353–363.
Article
52. Ky A, Sohn N, Weinstein MA, Korelitz BI. Carcinoma arising in anorectal fistulas of Crohn's disease. Dis Colon Rectum. 1998; 41:992–996. PMID: 9715154.
Article
53. Higashi D, Katsuno H, Kimura H, et al. Current state of and problems related to cancer of the intestinal tract associated with Crohn's disease in Japan. Anticancer Res. 2016; 36:3761–3766. PMID: 27354651.
54. Delaunoit T, Limburg PJ, Goldberg RM, Lymp JF, Loftus EV Jr. Colorectal cancer prognosis among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006; 4:335–342. PMID: 16527697.
Article
55. Adler J, Rangwalla SC, Dwamena BA, Higgins PD. The prognostic power of the NOD2 genotype for complicated Crohn's disease: a meta-analysis. Am J Gastroenterol. 2011; 106:699–712. PMID: 21343918.
Article
56. Zhang Z, Li C, Zhao X, et al. Anti-Saccharomyces cerevisiae antibodies associate with phenotypes and higher risk for surgery in Crohn’s disease: a meta-analysis. Dig Dis Sci. 2012; 57:2944–2954. PMID: 22669207.
Article
57. Mow WS, Vasiliauskas EA, Lin YC, et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn’s disease. Gastroenterology. 2004; 126:414–424. PMID: 14762777.
Article
58. Dubinsky MC, Lin YC, Dutridge D, et al. Serum immune responses predict rapid disease progression among children with Crohn’s disease: immune responses predict disease progression. Am J Gastroenterol. 2006; 101:360–367. PMID: 16454844.
Article
59. de Vries AB, Janse M, Blokzijl H, Weersma RK. Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis. World J Gastroenterol. 2015; 21:1956–1971. PMID: 25684965.
Article
60. Hashimoto E, Ideta M, Taniai M, et al. Prevalence of primary sclerosing cholangitis and other liver diseases in Japanese patients with chronic ulcerative colitis. J Gastroenterol Hepatol. 1993; 8:146–149. PMID: 8471752.
Article
Full Text Links
  • IR
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr